✍️ For The Guardian, Julia Kollewe reports on #AMRB26 findings, highlighting a 35% drop in antimicrobial R&D & uneven industry engagement. With #DrugResistance rising, can #innovation keep up? Read more➡️ https://tinyurl.com/nhcfx7uj #AMR #pharma #HealthEquity #GlobalHealth
The antimicrobial pipeline is shrinking. #AMRB26 finds a 35% decline in pipeline projects from large research-based companies since 2021, underscoring the urgency of sustaining #innovation while ensuring new treatments reach patients most in need. Read more➡️ tinyurl.com/susrpke
Access to anti-infectives depends on affordability & availability in practice, not supply alone. #AMRB26 shows access barriers are shaped by local contexts & require tailored strategies, yet only 44% of products are covered by such strategies. Read more➡️ tinyurl.com/4nnzk6ry
#WorldTBDay is a reminder that #TB remains one of the deadliest infectious diseases. Yet tools to treat drug-resistant forms risk falling behind. #AMRB26 shows a 35% decline in antimicrobial R&D by #pharma, raising concerns for diseases like TB. Read more➡️ tinyurl.com/4nnzk6ry
How is the #pharma industry performing in the fight against #AMR? #AMRB26 presents a mixed picture. While some companies are making progress in specific areas, overall industry performance has declined since 2021 & progress remains uneven. Learn more👉
accesstomedicinefoundation.org/insights-res...
Discussions at yesterday’s #AMRB26 launch in London highlighted the fragility of the #AMR landscape. Participants emphasised that stronger partnerships, coordinated incentives & responsible use of #antibiotics will be key to sustaining progress.
🔗 accesstomedicinefoundation.org/news/tools-t...
NOW ONLINE: The 2026 AMR Benchmark #AMRB26 finds pockets of progress in how #pharma companies are tackling #AMR but #DrugResistance continues to outpace industry-wide efforts, underscoring the urgent need for more comprehensive action.
Read the report👉 accesstomedicinefoundation.org/news/tools-t...
